807 related articles for article (PubMed ID: 22445431)
1. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
Bahamondes MV; Monteiro I; Castro S; Espejo-Arce X; Bahamondes L
Hum Reprod; 2010 May; 25(5):1158-64. PubMed ID: 20185512
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
Modesto W; Bahamondes MV; Bahamondes L
Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
[TBL] [Abstract][Full Text] [Related]
4. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
[TBL] [Abstract][Full Text] [Related]
5. Body weight and body composition of depot medroxyprogesterone acetate users.
Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
[TBL] [Abstract][Full Text] [Related]
6. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
Yela DA; Monteiro IM; Bahamondes LG; Del Castillo S; Bahamondes MV; Fernandes A
Rev Assoc Med Bras (1992); 2006; 52(1):32-6. PubMed ID: 16622536
[TBL] [Abstract][Full Text] [Related]
7. Weight change at 12 months in users of three progestin-only contraceptive methods.
Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
[TBL] [Abstract][Full Text] [Related]
8. Selection and performance of the levonorgestrel-releasing intrauterine system.
Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
[TBL] [Abstract][Full Text] [Related]
9. Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
Selim MF; Hussein AF
Contraception; 2013 Apr; 87(4):396-403. PubMed ID: 23332246
[TBL] [Abstract][Full Text] [Related]
10. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
11. Changes in body composition in women using long-acting reversible contraception.
Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
[TBL] [Abstract][Full Text] [Related]
12. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
[TBL] [Abstract][Full Text] [Related]
13. Uptake of the levonorgestrel intrauterine system among recent postpartum women in Kenya: factors associated with decision-making.
Hubacher D; Masaba R; Manduku CK; Veena V
Contraception; 2013 Jul; 88(1):97-102. PubMed ID: 23566383
[TBL] [Abstract][Full Text] [Related]
14. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.
Seeber B; Ziehr SC; Gschlieβer A; Moser C; Mattle V; Seger C; Griesmacher A; Concin N; Concin H; Wildt L
Contraception; 2012 Oct; 86(4):345-9. PubMed ID: 22402256
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
[TBL] [Abstract][Full Text] [Related]
16. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
Pakarinen P; Lähteenmäki P; Rutanen EM
Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
[TBL] [Abstract][Full Text] [Related]
17. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
18. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use.
Rönnerdag M; Odlind V
Acta Obstet Gynecol Scand; 1999 Sep; 78(8):716-21. PubMed ID: 10468065
[TBL] [Abstract][Full Text] [Related]
19. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
[TBL] [Abstract][Full Text] [Related]
20. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
